PhotoCure ASA (OSL:PHO)
kr 49.3 0.4 (0.82%) Market Cap: 1.34 Bil Enterprise Value: 1.05 Bil PE Ratio: 94.81 PB Ratio: 2.67 GF Score: 78/100

Q2 2021 Photocure ASA Earnings Call Transcript

Aug 11, 2021 / 03:30PM GMT
Release Date Price: kr127.1 (-9.99%)
Daniel Schneider
Photocure ASA - President & CEO

All right. Well, welcome. This is Dan Schneider, President and CEO of Photocure. With me today is Erik Dahl, CFO, and you've plugged into the Photocure results for second quarter 2021.

Next slide. Just reminder, disclaimers are in fact for today's presentation. Next slide. Top line second quarter highlights. We've had progress in both commercial regions despite the continued pandemic, COVID-19. We had 66% revenue growth in the second quarter. That's 87% positive constant currency. EBITDA of positive NOK 5.8 million. We also had 3 key study publications. One of them actually emanating from our own U.S. registry, which is fantastic. And partnership activities continue with Asieris dosing the first patient for Cevira in Europe, [pivots] Phase III trial. And Genotests in Chile filed its MAA on a fast track review and expect more information as time goes on.

Next slide. I'd like to give you a really quick COVID-19 update. Access restrictions continued due to the third and fourth waves. We're now entering into the delta wave, unfortunately

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot